Efficacy and Safety of Rimegepant for Migraine Patients: A Meta-analysis of Randomized Controlled Studies

Migraine

(2022) Michel D. Ferrari et al.   Nature Reviews Disease Primers

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

(2022) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Acute Treatments for Episodic Migraine in Adults

(2021) Juliana H. VanderPluym et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Diagnosis and management of migraine in ten steps

(2021) Anna K. Eigenbrodt et al.   Nature Reviews Neurology

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

(2021) Uwe Reuter et al.   CEPHALALGIA

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

(2021) Rebecca C. Burch et al.   HEADACHE

Efficacy and safety of eptinezumab in patients with chronic migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

(2020) Theo Vos et al.   LANCET

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

(2020) Robert Croop et al.   LANCET

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

(2019) Robert Croop et al.   LANCET

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

(2019) Richard B. Lipton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

CGRP as the target of new migraine therapies — successful translation from bench to clinic

(2018) Lars Edvinsson et al.   Nature Reviews Neurology

Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences

(2018) Richard B. Lipton et al.   HEADACHE

Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Lars Jacob Stovner et al.   LANCET NEUROLOGY

Galcanezumab in chronic migraine

(2018) Holland C. Detke et al.   NEUROLOGY

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

Treatment Adherence in Patients With Headache: A Systematic Review

(2014) Rachelle R. Ramsey et al.   HEADACHE

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

(2013) Ronald Marcus et al.   CEPHALALGIA

Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine

(2012) Guanglin Luo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1

(2012) S.D. Silberstein et al.   NEUROLOGY